Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting